SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla’s arm completes sale of entire shareholding in Wellthy

07 Mar 2024 Evaluate

Cipla’s wholly owned subsidiary -- Goldencross Pharma (Goldencross) has completed the sale of its entire shareholding in Wellthy Therapeutics (Wellthy) in terms of the definitive agreement executed on March 06, 2024. The consideration received from such sale is Rs 59.71 lakh for the sale of 5,32,121 Compulsorily Convertible Preference Shares (CCPS) and 10 equity shares held in Wellthy.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. 

Cipla Share Price

1238.30 7.55 (0.61%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×